Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zinc sulfate added to toripalimab + disitamab vedotin in HER2-positive muscle-invasive bladder urothelial carcinoma
ChiCTR2600128788Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab, disitamab vedotin and zinc in transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Tongji Hospital. Primary endpoints: Serum zinc concentration during zinc supplementation and Complete response rate at 3 months after treatment completion. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
toripalimabdisitamab vedotinzinc
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2600128788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128788.